You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditional vaccines have contributed greatly to public health, they have some limitations especially in the context of operati ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  2. Hardened, Optically-Based Temperature Characterization of Detonation Environments

    SBC: SA PHOTONICS, LLC            Topic: DTRA19B001

    Improving the effectiveness of counter-WMD operations requires improved understanding of weapon-target interaction. Specifically, time-resolved measurements of temperature and composition are required to allow temporal evolution of a detonation fireball. To address this need, SA Photonics will develop MONITOR, a laser-based temperature diagnostic that will enable wide dynamic range temperature mea ...

    STTR Phase I 2020 Department of DefenseDefense Threat Reduction Agency
  3. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government